Medicine composition used for treating neurodegenerative disease as well as preparation method and application thereof

A technology of neurodegeneration and composition, which is applied in the direction of drug combination, nervous system diseases, and pharmaceutical formulations. It can solve the problems of dose ratio and further research, and achieve superior curative effect.

Active Publication Date: 2013-07-03
CHENGDU UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This patent application adopts an orthogonal experiment design scheme based on the amount of conventional clinical crude drugs. It is believed that the compatibility ratio of Scutellaria baicalensis, Chuanxiong and Angelica sinensis (15:10:10) is the best ratio. However, the curative effect of drug prescriptions is often affected by factors such as dose ratio, disease variation, and body sensitivity to drugs, so the optimal ratio calculated based on the amount of conventional crude drugs needs to be further studied

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition used for treating neurodegenerative disease as well as preparation method and application thereof
  • Medicine composition used for treating neurodegenerative disease as well as preparation method and application thereof
  • Medicine composition used for treating neurodegenerative disease as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Weigh 250g of raw materials Scutellaria baicalensis, 180g of Rhizoma Chuanxiong, and 60g of Angelica sinensis, add 500g of auxiliary materials starch to granulate, 10g of magnesium stearate, 250g of dextrin, and 250g of microcrystalline cellulose, uniformly prepare granules, and press into tablets to obtain tablets.

Embodiment 2

[0021] Weigh 300 g of raw materials Scutellaria baicalensis, 180 g of Rhizoma Chuanxiong, and 60 g of Angelica sinensis, add 500 g of auxiliary materials starch to granulate, 10 g of magnesium stearate, 250 g of dextrin, and 250 g of microcrystalline cellulose, uniformly prepare granules, and press into tablets to obtain tablets.

Embodiment 3

[0023] Weigh 300g of raw materials Scutellaria baicalensis, 200g of Rhizoma Chuanxiong, and 80g of Angelica sinensis, add 600g of auxiliary materials starch to granulate, 12g of magnesium stearate, 260g of dextrin, and 260g of microcrystalline cellulose, uniformly prepare granules, and press into tablets to obtain tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of traditional Chinese medicines and in particular provides a medicine composition used for treating neurodegenerative disease. The medicine composition used for treating neurodegenerative disease is prepared from the following bulk pharmaceutical chemicals in parts by weight: 25-40 parts of scutellaria baicalensis, 18-30 parts by weight of ligusticum wallichii and 6-10 parts of Chinese angelica. The invention also provides a preparation method and a concrete purpose of the medicine composition. Pharmacodynamic experiment proves that the medicine composition has a better therapeutical effect on degenerative change of a central nervous system according to related objective indicators of a mouse dementia model, a vascular rat dementia model, a mouse pia mater microcirculation model and the like in an experimental group.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating neurodegenerative diseases, in particular to a pharmaceutical composition for treating and alleviating senile dementia, vascular dementia or mild cognitive impairment, its preparation method and application, which belong to the traditional Chinese medicine technology field. Background technique [0002] Alzheimer's disease refers to the senile disease caused by a variety of reasons, with cognitive impairment as the main clinical manifestation, and is a clinical syndrome. In recent years, with the aging of the population in all countries in the world, the incidence of Alzheimer's disease has shown a sharp upward trend, and its death rate ranks fourth after heart disease, tumor and stroke. According to statistics, the prevalence rate is about 5% in the population over 60 years old in my country, about 6 million, and increases with age. The pathological changes of senile dementia are mai...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/539A61P25/00A61P25/28
Inventor 徐世军代渊
Owner CHENGDU UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap